环丙沙星、诺氟沙星、恶喹酸、西诺沙星和萘啶酸的抗菌活性。
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
作者信息
Barry A L, Jones R N, Thornsberry C, Ayers L W, Gerlach E H, Sommers H M
出版信息
Antimicrob Agents Chemother. 1984 May;25(5):633-7. doi: 10.1128/AAC.25.5.633.
Abstract
In vitro studies were performed comparing ciprofloxacin (Bay o 9867) and norfloxacin with three related organic acids. Ciprofloxacin was two to eight times more active than norfloxacin against 658 bacterial isolates representing 30 species. For all species tested, ciprofloxacin MICs for 90% inhibition were less than or equal to 2.0 micrograms ml. Additional tests with 5,994 isolates detected only 37 (0.6%) strains resistant to 2.0 micrograms of ciprofloxacin per ml and 106 (1.8%) resistant to 1.0 micrograms/ml. Only 6 (0.1%) of the 5,994 strains were resistant to 16 micrograms of norfloxacin per ml, and 129 (2.1%) were resistant to 4.0 micrograms/ml. The majority of resistant strains were streptococci or Pseudomonas spp. Resistance among the Enterobacteriaceae was extremely rare (i.e., greater than 99.8% susceptible to both drugs.
摘要
进行了体外研究，比较环丙沙星（拜耳O 9867）和诺氟沙星与三种相关有机酸的抗菌活性。环丙沙星对代表30个菌种的658株细菌的活性比诺氟沙星高2至8倍。对于所有测试菌种，环丙沙星抑制90%细菌生长的最低抑菌浓度（MIC）小于或等于2.0微克/毫升。对5994株细菌进行的额外测试仅检测到37株（0.6%）对每毫升2.0微克环丙沙星耐药，106株（1.8%）对每毫升1.0微克环丙沙星耐药。在5994株细菌中，只有6株（0.1%）对每毫升16微克诺氟沙星耐药，129株（2.1%）对每毫升4.0微克诺氟沙星耐药。大多数耐药菌株为链球菌或假单胞菌属。肠杆菌科中的耐药情况极为罕见（即对两种药物的敏感性均大于99.8%）。
相似文献
1
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.环丙沙星、诺氟沙星、恶喹酸、西诺沙星和萘啶酸的抗菌活性。
Antimicrob Agents Chemother. 1984 May;25(5):633-7. doi: 10.1128/AAC.25.5.633.
2
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.体外筛选耐药菌群体后，西诺沙星、环丙沙星、DJ - 6783、依诺沙星、萘啶酸、诺氟沙星和恶喹酸之间的交叉耐药性。
Antimicrob Agents Chemother. 1984 Jun;25(6):775-7. doi: 10.1128/AAC.25.6.775.
3
In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.诺氟沙星与萘啶酸、西诺沙星和恶喹酸的体外比较。
Arzneimittelforschung. 1983;33(12):1623-7.
4
Comparative in vitro activity of ciprofloxacin and five other quinoline derivatives against gram-negative isolates.环丙沙星与其他五种喹啉衍生物对革兰氏阴性菌分离株的体外活性比较
Drugs Exp Clin Res. 1985;11(5):331-4.
5
In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.环丙沙星、诺氟沙星、吡哌酸、西诺沙星和萘啶酸对沙眼衣原体的体外活性
Antimicrob Agents Chemother. 1984 Jan;25(1):123-4. doi: 10.1128/AAC.25.1.123.
6
Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.环丙沙星（拜奥9867）、诺氟沙星、吡哌酸和萘啶酸的比较活性。
Antimicrob Agents Chemother. 1983 Aug;24(2):302-4. doi: 10.1128/AAC.24.2.302.
7
In vitro activity of ciprofloxacin (Bay o 9867).环丙沙星（拜耳o 9867）的体外活性。
Antimicrob Agents Chemother. 1983 Oct;24(4):568-74. doi: 10.1128/AAC.24.4.568.
8
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.新型喹啉衍生物Bay 09867与其他抗菌药物的体外活性比较。
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
9
The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.环丙沙星与诺氟沙星和萘啶酸的体外活性比较。
J Antimicrob Chemother. 1984 Apr;13(4):325-31. doi: 10.1093/jac/13.4.325.
10
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.八种新型喹诺酮类药物与萘啶酸的体外活性比较
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
引用本文的文献
1
rhamnolipids stabilize human rhinovirus 14 virions.鼠李糖脂可稳定人鼻病毒14病毒粒子。
bioRxiv. 2025 Jun 4:2025.06.04.657910. doi: 10.1101/2025.06.04.657910.
2
Dual-species proteomics and targeted intervention of animal-pathogen interactions.动物-病原体相互作用的双物种蛋白质组学及靶向干预
J Adv Res. 2024 Sep 2. doi: 10.1016/j.jare.2024.08.038.
3
Propagation of (Maxim.) Koidz. from immature seeds using a new sterilization procedure.利用一种新的消毒程序从未成熟种子繁殖（马克西姆）小泉。
Plant Biotechnol (Tokyo). 2020 Sep 25;37(3):353-357. doi: 10.5511/plantbiotechnology.20.0310a.
4
Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An Analysis.基于喹啉的SARS-CoV-2 3CL蛋白酶和RNA依赖性RNA聚合酶抑制剂以及刺突受体结合结构域-血管紧张素转换酶2抑制剂用于抗COVID-19的药物再利用分析
Front Microbiol. 2020 Jul 23;11:1796. doi: 10.3389/fmicb.2020.01796. eCollection 2020.
5
Recent Bio-Advances in Metal-Organic Frameworks.金属有机框架的最新生物进展。
Molecules. 2020 Mar 12;25(6):1291. doi: 10.3390/molecules25061291.
6
Transferable Mechanisms of Quinolone Resistance from 1998 Onward.1998 年以来喹诺酮类耐药的可转移机制。
Clin Microbiol Rev. 2019 Aug 14;32(4). doi: 10.1128/CMR.00007-19. Print 2019 Sep 18.
7
Montmorillonite-norfloxacin nanocomposite intended for healing of infected wounds.用于治疗感染性伤口的蒙脱石-诺氟沙星纳米复合材料。
Int J Nanomedicine. 2019 Jul 10;14:5051-5060. doi: 10.2147/IJN.S208713. eCollection 2019.
8
Antibiotic resistance of Gram-negative benthic bacteria isolated from the sediments of Kardzhali Dam (Bulgaria).从保加利亚卡尔扎利大坝沉积物中分离出的革兰氏阴性底栖细菌的抗生素耐药性
Biotechnol Biotechnol Equip. 2015 Mar 4;29(2):274-280. doi: 10.1080/13102818.2014.998160. Epub 2015 Jan 20.
9
Perturbation of iron homeostasis promotes the evolution of antibiotic resistance.铁稳态的扰动促进抗生素耐药性的演变。
Mol Biol Evol. 2014 Oct;31(10):2793-804. doi: 10.1093/molbev/msu223. Epub 2014 Jul 24.
10
Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis).协同导向的草药分馏：以白毛茛（Hydrastis canadensis）为例。
J Nat Prod. 2011 Jul 22;74(7):1621-9. doi: 10.1021/np200336g. Epub 2011 Jun 10.
本文引用的文献
1
Pharmacokinetics and tissue penetration of ciprofloxacin.环丙沙星的药代动力学及组织穿透性
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
2
Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.诺氟沙星（MK - 0366，AM - 715）：体外活性及与其他有机酸的交叉耐药性，包括纸片扩散法检测的质量控制限度
Diagn Microbiol Infect Dis. 1983 Jun;1(2):165-72. doi: 10.1016/0732-8893(83)90047-0.
3
In vitro activity of ciprofloxacin (Bay o 9867).环丙沙星（拜耳o 9867）的体外活性。
Antimicrob Agents Chemother. 1983 Oct;24(4):568-74. doi: 10.1128/AAC.24.4.568.
4
Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.环丙沙星（拜奥9867）、诺氟沙星、吡哌酸和萘啶酸的比较活性。
Antimicrob Agents Chemother. 1983 Aug;24(2):302-4. doi: 10.1128/AAC.24.2.302.
5
In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.环丙沙星、诺氟沙星和萘啶酸的体外活性。
Eur J Clin Microbiol. 1983 Apr;2(2):111-5. doi: 10.1007/BF02001575.
6
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.新型喹啉衍生物Bay 09867与其他抗菌药物的体外活性比较。
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.
7
Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).诺氟沙星（MK - 0366，AM - 715）纸片扩散药敏试验的暂行解释标准。
Antimicrob Agents Chemother. 1983 Feb;23(2):256-60. doi: 10.1128/AAC.23.2.256.
8
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.喹诺酮羧酸类药物诺氟沙星的体外活性与β-内酰胺类、氨基糖苷类及甲氧苄啶的比较。
Antimicrob Agents Chemother. 1982 Jul;22(1):23-7. doi: 10.1128/AAC.22.1.23.
Zotero 插件